BridgeBio Oncology Therapeutics Inc BBOT
$9.08
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
BBOT Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, BridgeBio Oncology Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
BridgeBio Oncology Therapeutics Inc. Stock Analysis BBOT
United States Health Care Small Cap Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
BridgeBio Oncology Therapeutics Inc (BBOT) Chart
Financial Metrics & Statements of BridgeBio Oncology Therapeutics Inc (BBOT)
FAQ's for BridgeBio Oncology Therapeutics Inc (BBOT)
- As of August 2026, BridgeBio Oncology Therapeutics Inc BBOT is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes BridgeBio Oncology Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in BridgeBio Oncology Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of BridgeBio Oncology Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of BridgeBio Oncology Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of BridgeBio Oncology Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for BridgeBio Oncology Therapeutics Inc (BBOT)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
